/

Research

100% of Psychonauts Visited Other Worlds Tripping on DMT for StudyShutterstock

100% of Psychonauts Visited Other Worlds During DMT Study

And 94% reported meeting with otherworldly beings during "profound and highly intense experiences."
LSD Microdosing Study Finds 'No Residual Effects' on Mood or CognitionShutterstock

LSD Microdosing Study Finds ‘No Residual Effects’ on Mood or Cognition

Another study concludes with results challenging the increasingly popular narrative that microdosing psychedelics improves mood and cognitive function.
Is ‘The Trip’ Essential to The Psychedelic Experience?

Is ‘The Trip’ Essential to The Psychedelic Experience?

Biology and experience are tough to separate, but some researchers are exploring the possibility of non-hallucinogenic psychedelics as a mental health treatment. This begs the question: what do we lose, and what do we gain when we take the trip out of the psychedelic experience?
Psychedelics Can Change Your View on the Nature of Reality

Psychedelics Can Change Your View on the Nature of Reality

A recent study has found that psychedelics can fundamentally change your core beliefs about the nature of fate, reality, and consciousness.

Texas Further Embraces Psychedelics with Launch of Center for Psychedelic Research and Therapy

Research will focus on how various psychedelics can be used under proper supervision and guidance to treat severe depression, anxiety and PTSD.
Can Psychedelics Treat Alzheimer's Disease?

Can Psychedelics Treat Alzheimer’s Disease?

,
Since substances such as LSD and psilocybin have powerful anti-inflammatory properties, researchers argue that the microbiological action of psychedelics may therefore help fight brain-based symptoms in early Alzheimer’s patients.
FDA Green Lights Tryp Therapeutics' Psilocybin Study on Binge Eating DisorderShutterstock.com

FDA Green Lights Tryp Therapeutics’ Psilocybin Study on Binge Eating Disorder

The pharmaceutical company developing psilocybin-based compounds for diseases with unmet medical needs estimates a $2.9 billion market potential for such a treatment.

Understanding HPPD to Prioritize Harm Reduction of a Very Real Psychedelic Risk

“HPPD is precisely the kind of risk that could fall through the cracks," says journalist Ed Prideaux, who suffers from the condition and advocates for more research.

Compass Pathways Study Finds SSRI Drugs Did Not Impede Psilocybin’s Therapeutic Effect

Chief Medical Officer Guy Goodwin calls study "a strong signal that COMP360 psilocybin therapy could be an adjunctive treatment to SSRI antidepressant as well as a monotherapy."

© 2023 Psychedelic Spotlight. | Owned and operated by PSYC Media Corporation, Inc. a US publicly traded company (OTCPink: PSYC) | All Rights Reserved.